FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 07/2025”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US Healthcare & Life Sciences sector.
As of the tip of July 2025 we recognized the next present VC developments in the USA:
-
Complete Healthcare & Life Sciences funding reached EUR 6,654m (+18% vs. 2024
-
Biotech/Pharma obtained 41% of the entire funding quantity (EUR 2,704m) with oncology being the main indication (23% of BioTech)
-
In July, Nuclidium (Switzerland) secured the best transaction quantity with EUR 84m, adopted by Artios (Nice Britain) with EUR 70m and Ultromics (Nice Britain) with EUR 50m
-
GV (United States) is essentially the most lively investor (by deal quantity in 2025), adopted by Alphabet (United States) and Thrive Capital (United States)
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink